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Abstract
Background: Even though the efficacy of Intermittent Preventive Treatment in infants (IPTi) with Sulfadoxine-
Pyrimethamine (SP) against clinical disease and the absence of its interaction with routine vaccines of the
Expanded Immunization Programme (EPI) have been established, there are still some concerns regarding the
addition of IPTi, which may increase the work burden and disrupt the routine EPI services especially in Africa
where the target immunization coverage remains to be met. However IPTi may also increase the adherence of the
community to EPI services and improve EPI coverage, once the benefice of strategy is perceived.
Methods: To assess the impact of IPTi implementation on the coverage of EPI vaccines, 22 health areas of the
district of Kolokani were randomized at a 1:1 ratio to either receive IPTi-SP or to serve as a control. The EPI
vaccines coverage was assessed using cross-sectional surveys at baseline in November 2006 and after one year of
IPTi pilot-implementation in December 2007.
Results: At baseline, the proportion of children of 9-23 months who were completely vaccinated (defined as children
who received BGG, 3 doses of DTP/Polio, measles and yellow fever vaccines) was 36.7% (95% CI 25.3% -48.0%). After
one year of implementation of IPTi-SP using routine health services, the proportion of children completely vaccinated
rose to 53.8% in the non intervention zone and 69.5% in the IPTi intervention zone (P <0.001).
The proportion of children in the target age groups who received IPTi with each of the 3 vaccinations DTP2, DTP3
and Measles, were 89.2% (95% CI 85.9%-92.0%), 91.0% (95% CI 87.6% -93.7%) and 77.4% (95% CI 70.7%-83.2%)
respectively. The corresponding figures in non intervention zone were 2.3% (95% CI 0.9% -4.7%), 2.6% (95% CI 1.0%
-5.6%) and 1.7% (95% CI 0.4% - 4.9%).
Conclusion: This study shows that high coverage of the IPTi can be obtained when the strategy is implemented
using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the
district of Kolokani, Mali.
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Background
Malaria is one of biggest killer of infants and children in
sub-Saharan Africa. In the absence of a vaccine against
malaria, the intermittent preventive treatment of malaria
in infant (IPTi) has been developed to reduce the bur-
den of malaria in infants. IPTi consists on the adminis-
tration of a curative dose of antimalarials at the time of
EPI vaccination during the first year of life regardless of
the presence of symptoms or infection [1]. Several ran-
domized control studies of IPTi with Sulfadoxine-pyri-
methamine (SP) in different parts of Africa have shown
that the strategy is efficacious in preventing clinical epi-
sodes of malaria by 30% and incidence of anemia by
20% [2] although no efficacy was found in an area
where the resistance to SP was 82% [3]. The strategy is
effective and well accepted by the communities [4-7]. It
has also been established that the administration of SP
at the time of EPI vaccines shows no negative interac-
tion with these vaccines [8-10] and no safety issue was
found [11,12]. A consortium was established in 2003 to
generate scientific evidence required to inform and
speed up the process of going from strategy into policy
[1]. In 2009 the WHO has recommended IPTi-SP as
policy for malaria control in areas where the malaria
transmission is moderate- to -high and where the para-
site resistance to SP is not high (prevalence of dhps 540
mutation <50%) [13]. Even though the efficacy, the
absence of interaction with EPI vaccines and safety of
IPTi are well established, there are still concerns that
addition of IPTi will result in an increase in the work
burden and will disrupt the routines EPI services espe-
cially in Africa where the target EPI vaccines coverage
remains to be met. However IPTi may also increase the
adherence of the community to EPI services and
improve EPI coverage, once the benefit of the strategy is
perceived [14,15].
Mali has one of the highest infant mortality rate in the
world estimated at 119 per 1000 (http://www.unicef.org/
french/infobycountry/mali_statistics.html) along with a
high malaria burden. Malaria is reported by the health
centers as a primary cause of the morbidity and mortal-
ity according routine health reports [16] and is sup-
ported by more rigorous cohort studies [17,18]. P.
falciparum resistance to SP remains low in Mali [19,20]
and the prevalence of mutation dhps 540 is less than 5%
[21,22]. The proportion of children completely vacci-
nated with EPI vaccines in Mali remained below 50%
according to health surveys in 2001 and 2006 [23,24].
This study aimed to evaluate the impact of the IPTi-SP
implementation on the coverage of EPI vaccines after
one year of intervention in a context of a large pilot




The study was conducted in the district of Kolokani,
Mali. The district of Kolokani is an administrative sub-
division of the region of Koulikoro, in Mali. The town
of Kolokani is located at about 140 km north of
Bamako. The district covers 14,380 km2, divided into 22
health sub-districts. Each health sub-district is com-
posed of several villages. The total population was
208,317 inhabitants with children under 1 year repre-
senting about 4% of the total population. Malaria is
hyperendemic in the region with parasite prevalence in
children under 5 years of 45% during the dry season
and above 70% during the rainy season [21]. Heath ser-
vices are provided in the district through 6 physicians, 2
midwifes, 17 nurses, 19 matrones and 18 vaccinators.
Study Design
The study was an open cluster-randomized trial. The 22
health areas (sub-districts) of the district of Kolokani
were randomized in a 1:1 ratio with the intervention in
11 health areas and the other 11 serving as controls for
the assessment of the impact of IPTi implementation on
EPI vaccines and other health interventions coverage as
well as its impact on the P. faciparum resistance to SP.
IPTi was implemented from December 2006 to Decem-
ber 2007 and children 0-23 months were surveyed at
baseline and one year after to assess of the impact of
IPTi implementation on EPI vaccines and other health
interventions coverage [21].
IPTi implementation
The intervention consisted on the administration to
infants of ½ tablet of SP along with EPI vaccines (DTP2,
DTP3 and Measles/Yellow fever vaccine) from December
2006 to December 2007. Prior to the randomization of
the health areas, IPTi implementation tools (training
modules, supports for data collection, monitoring and
evaluation, information and communication) were devel-
oped by working groups including personnel of the
health district, and the regional heath directorate. Sup-
ports for child health interventions (vaccination card,
vaccines registration forms, monitoring and evaluation
forms etc...) were modified to allow the recording of the
administration of the SP along with EPI vaccines and the
health interventions. Forms for procurement and supply
of SP were developed to be used along with those of
other health interventions. Communities’ leaders were
sensitized and health of the health staffs were trained.
Randomization
At the end of training session of staff of communities
health centers, the 22 health areas (sub-districts) of the
district of Kolokani were randomized into a 1:1 ratio
into two zones (intervention zone and control zone).
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For transparency and better adhesion of the community
health centers representatives, a manual randomisation
was done publically as follow. The health areas were
numbered from 1 to 22 and each number was written
on piece of paper that was folded. The 22 pieces of
paper were then mixed and placed in box and 11 of
them were randomly drawn to serve as intervention
areas by one of the trainees in presence of the represen-
tatives of the 22 communities’ health centers (see addi-
tional file 1).
Assessment of the EPI vaccines and health interventions
coverage
Two cross-sectional surveys were performed, one at
baseline in November 2006 prior to the beginning of
IPTi implementation and another in December 2007
after one year of IPTi implementation. Thirty clusters
were selected using a random sampling with probability
proportional to the size of the population size. In each
cluster (location), a sample of about 35 children in
November 2006 and about 70 children in December
2007 aged 0-23 months were randomly selected and sur-
veyed using the WHO method of evaluation of vaccine
coverage [25]. An interviewer-administered question-
naire was used to obtain data using modified UNICEF
multiple indicators cluster surveys questionnaire (http://
www.childinfo.org/mics2_questionnaire.html). Parents or
guardians of children aged 0-23 months in selected
households were questioned about the EPI vaccines and
other health interventions. Information on EPI vaccina-
tion cards was recorded for each child and in its
absence, questions regarding the EPI vaccines were
asked and responses recorded. The information on vac-
cination were collected by interview only when the vac-
cination card was not available. When the card is not
available and a parent answers a particular question as
“do not know” this information is considered missing
and ignored in the analysis. The interviews were con-
ducted in local language and by two interviewers in
each household. Main indicators included child immuni-
zations and IPTi coverage, use of insecticide-impreg-
nated bed net (ITN) during the previous night, and
child receiving vitamin A supplementation. Filled ques-
tionnaires were verified at the end of each day by a
supervisor and corrected if necessary.
Endpoints
The primary endpoint was the proportion of children
aged 9-23 months completely vaccinated. Children of 9-
23 months were considered completely vaccinated if
they had had BCG, at least 3 doses of DTP, Polio,
measles and yellow fever vaccines. Secondary endpoints
are: i) absolute proportions of children who received
appropriate doses of each of EPI vaccines (one dose of
BCG, 3 doses for Polio, 3 doses for DTP, one dose for
measles vaccine, one dose of yellow fever vaccine), vita-
min A supplementation, and who slept under ITN and
ii) relative proportion of children who received indivi-
dual doses of IPTi.
Sample size
Sample size for the baseline survey was estimated using
the following assumptions. Based on a precision of 6%
and alpha error of 5% and DTP3 coverage of two thirds
(67%), a sample of 472 children was selected using a
cluster effect of 2. This sample size was doubled to take
into account analysis for specific age categories and
increased by 10% to take into account missing informa-
tion, making a total sample size of 1,050 children aged
0-23 months. During the second survey after one year
of implementation, the same number of 1,050 children
was sampled in each zone (intervention and non inter-
vention) to allow estimates of vaccine coverage in each
zone and comparisons between them. This will provide
90% power or more based on a proportion of completely
vaccinated between 50% and 67% and a non-inferiority
margin of 10% with two tailed significance level of 5%.
Data management and analysis
Data were double entered and reconciled using Epi Info
version 6 (CDC Atlanta). The cleaned database was
exported to Stata 9 (Houston Texas, USA) for the analy-
sis. Vaccine coverage was determined using the informa-
tion on vaccination card and from interview and was
defined as the proportion of children who receive the
vaccine based on the information on the card or the
vaccination history provided by mothers or guardians
among the total number of children surveyed in the tar-
get age group. Target age groups were defined as age
ranges starting from the age at which the vaccine is
given according to EPI vaccination schedule up to 23
months of age (i.e. 0-23 months for BGG and, 4-23
months for the three doses of DTP and Polio vaccines
and 9-23 months for measles and yellow fever vaccines).
Children of 9-23 months were considered completely
vaccinated if they had had BCG, at least 3 doses of
DTP, Polio, measles and yellow fever vaccines. Propor-
tions of children who received IPTi relative to the three
EPI vaccinations (DTP2, DTP3, and measles vaccines)
were computed as the number of children who had
documented doses 1, 2 or 3 of IPTi, divided by the
number of children with documented DTP2, DTP3, and
measles vaccines respectively. Coverage of IPTi1 and
IPTi2 were computed for children aged 4-15 months
and coverage of IPTi3 for those aged 9-15 months. Cov-
erage of ITN was defined as the number of children
who slept under ITN the night before divided by the
number of children surveyed, and coverage of vitamin A
supplementation was defined as the number of children
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6 -23 months who received a vitamin A supplementa-
tion divided by the number of children of this age group
surveyed. EPI vaccines and other health intervention’s
coverage were compared between the two zones at post-
intervention survey and before and after the IPTi imple-
mentation. The 95% confidence intervals were adjusted
for cluster design using cluster option in Stata (version
9, Houston Texas USA).
Ethical considerations
Ethical clearance was obtained from the Ethical Com-
mittee of the Faculty of Medicine Pharmacy and Dentis-
try of the University of Bamako, Mali, and informed
consent from a parent or legal guardian was obtained
prior to the enrollment of the child in the survey.
Results
Participants’ characteristics
At baseline, a total of 1050 children were surveyed,
51.9% were male. Vaccination card was available for
71.2% (95% CI 64.5% - 77.9%) of the children surveyed.
During the post -intervention survey, a total of 1051
children were surveyed in the intervention and 1055 in
the control zone. About 50.7% in the intervention zone
were male and 52.8% in the control zone (P = 0.34).
The proportion of children with EPI vaccination cards
was similar between intervention and control areas;
78.0% (95% CI 69.4% -86.6%) versus 80.1% (75.6% -
84.6%) (P = 0.65).
Coverage of IPTi after one year of implementation
The proportion of children in the target age groups who
received IPTi with each of the 3 vaccinations DTP2,
DTP3 and Measles, were 89.2% (95% CI 85.9%-92.0%),
91.0% (95% CI 87.6% -93.7%) and 77.4% (95% CI 70.7%-
83.2%) respectively. The corresponding figures in non
intervention zone were 2.3% (95% CI 0.9% -4.7%), 2.6%
(95%CI 1.0% -5.6%) and 1.7% (95% CI 0.4% - 4.9%).
Coverage of vaccines and other health interventions at
baseline and after implementation of IPTi
Coverage of the vaccines and health intervention at
baseline and after one year of IPTi implementation are
presented in Table 1.
At baseline, based on information from interviews and
vaccination cards, the proportions of children 4 -23
months who received BGG, 3 doses of DTP and Polio,
measles vaccine and yellow fever vaccine were 70.9%
(95% CI 62.7% -79.9%), 54.4% (95% CI.43.3% - 65.5%),
55% (95% CI 44.4% - 65.6%). The proportion of children
aged 6 months and above, who received Vitamin A sup-
plementation was 74.4% (95% CI 67.3% - 82.5%). Sleep-
ing under ITN was reported for 49.7% (95% CI 39.4% -
59.6%) of children aged 0-23 months. The proportion of
children 9-23 months who were completely vaccinated
(defined as children who received BGG, 3 doses of
DTP/Polio, measles and yellow fever vaccines) was
36.7% (95% CI 25.3% - 48.0%).
After one year implementation of IPTi, coverage of
vaccines and vitamin A supplementation increased sig-
nificantly in both control and intervention zones com-
pared to baseline. The proportion of children
completely vaccinated increased significantly from 36.7%
(95% CI 25.3%-48.0%) at baseline to 53.8% (95% CI
43.4% - 64.1%) (P < 0.001) in the control zone and to
69.5% (95% CI 64.2% - 74.7%), (P < 0.001) in the
Table 1 Coverage of EPI vaccines given with IPTi and other health interventions based on the information on
vaccination card and from interview at baseline and after IPTi implementation
Vaccines and
interventions












Baseline Control zone Intervention zone
n Coverage in %
(95% CI)
n Coverage in %
(95% CI)
n Coverage in %
(95% CI)
BCG 867 70.9% (62.7 - 79.1) 925 88.7% (82.6 - 94.9) 958 91.6% (88.7 - 94.6) 0.322 <0.001 <0.001
3 doses of DTP/
Polio
704 54.4% (43.3 - 65.5 718 60.2% (48.6 -71.7) 763 76.4% (69.5 -83.3) 0.007 0.03 <0.001
Measles 560 55.0% (44.4 - 65.6) 544 73.9% (67.6 - 80.1) 528 83.3% (78.8 - 87.9) 0.012 <0.001 <0.001
Yellow Fever 599 49.9% (38.7 - 61.1) 544 73.2% (67.2 - 79.1) 529 82.6% (77.8 - 87.4) 0.011 <0.001 <0.001
Completely
vaccinated
537 36.7% (25.3 - 48.0) 519 53.8% (43.4- 64.1) 511 69.5% (64.2 - 74.7) 0.005 <0.001 <0.001
Vitamin A
supplementation
720 74.4% (67.3 - 82.5) 723 83.7% (77.1- 90.3) 691 85.2% (78.0-92.5) 0.746 <0.001 <0.001
Use of ITN 1039 49.7% (39.4 - 59.6) 1045 52.7% (41.3 - 64.1) 1045 52.3% (43.7 - 61.0) 0.884 0.17 0.24
EPI: Expanded Programme on Immunization; IPTi: Intermittent Preventive Treatment in infants; BGG: Bacillus Calmette-Guérin vaccine; DTP: Diphtheria-Tetanus-
Pertussis vaccine; Polio: Poliomyelitis vaccine; ITN: Insecticide-impregnated bed net.
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intervention zone during the post-intervention survey.
The use of ITN was similar in post-intervention survey
compared to baseline.
With exception to BCG, the vaccines coverage during
the post-intervention survey was significantly higher
intervention zone compared to the non intervention
zone. The proportion of children completely vaccinated
was 69.5% (95% CI 64.2% -74.7%) in the intervention
zone and 53.8% (95%CI 43.4% - 64.1%) in the non inter-
vention zone (P = 0.005). The proportions of children
who received Vitamin A supplementation and propor-
tion of children using ITN were similar in the two
zones.
Discussion
This study showed a significant increase in the propor-
tion of children completely vaccinated after one year of
implementation of IPTi in the intervention zone com-
pared to non intervention (P = 0.005) and in each of
the two zones in compared to baseline (P < 0.001). The
increase in vaccine coverage in the intervention zone
compared to the non intervention zone occurred for all
the vaccines with the exception of BCG, the vaccine
that was not given with IPTi. The coverage of vitamin
A supplementation and use of ITN was also similar in
the two zones after one year of implementation. How-
ever, there was a significant increase in proportion of
children who received vitamin A in the each of the two
zones in post -intervention survey compared to baseline.
Possible reasons for this higher coverage in the IPTi
intervention zone compared to the non intervention
zone include more adhesion of the community because
of the high acceptability of the intervention, the addi-
tional motivation of the health workers and increase in
supervision of EPI activities due to the introduction of
IPTi-SP. Mothers’ knowledge of immunization or other
interventions is known to be positively correlated with
full immunization rates [23,24,26] and it is possible that
the adhesion of the community through information
and sensitization was responsible for this increase in
EPI vaccines coverage compared to baseline levels for
all the vaccines and for the fact that this increase was
more marked in the intervention zone compared to the
non intervention zone. Acceptability surveys conducted
in Mali (our unpublished data) and other countries in
sub-saharan Africa [15] have found that mothers like
IPTi and come more to health centers because i) they
are concern with malaria; ii) they think it is an anti-
pyretic (and post-vaccinal fever is one of the major bot-
tlenecks of EPI coverage) and iii) it is free. Even in the
context of maternal illiteracy, educating mothers about
the vaccines and vaccine-preventable diseases was
reported to be highly effective in increasing the immu-
nization coverage [27]. Positive mother’s perceptions
about IPTi have been reported in previous studies
[6,28].
Because in many countries in sub-Saharan Africa
including Mali there is a critical shortage of health ser-
vice providers [29], the concern that addition of IPTi-SP
to the vaccination package could result in a reduction in
the coverage of the EPI vaccines and other interventions
already delivered through EPI was legitimate. However,
not the full time of health center’s staff was used in
Mali and the addition of IPTi to the current EPI pack-
age is feasible without significant uptake of EPI services
as reported in Ghana [28].
As indicated in a previous study, the strategy is well
accepted by the health staff. The time used for IPTi
implementation is acceptable and was estimated to 12.4
minutes ranging from 1.6-28.9 minutes per nurse [30].
It represents about 11% of health workers’ time [31]
which is compatible with the current health staff and
activities in Mali.
The relatively closer and more regular supervisions,
especially at the beginning of the intervention, may have
also contributed to increased staff adherence and motiva-
tion that could have resulted in an increase in EPI vac-
cines coverage in post-intervention compared to baseline.
In line with other reports [23,24,32] the proportion of
children aged 9-23 months completely vaccinated was
only 36.7% in November 2006. However this proportion
increased significantly to 53.8% in non intervention and
69.5% in the intervention zone after one year of IPTi
implementation. This suggest that i) low vaccination
coverage should not be criteria preventing the introduc-
tion of IPTi into existent health systems; ii) IPTi can be
easily added to the routine immunizations of EPI with-
out impairing its coverage but on the contrary with the
possibility of boosting it; iii) cost and effectiveness stu-
dies [4,33] and assessment of the role of IPTi-SP in
infants [34-36] should consider a positive interaction
between IPTi and EPI vaccine coverage.
It is possible that the staff adhesion and the enthu-
siasm toward this new intervention have resulted in the
observed increase of EPI vaccination coverage in the
control zone compared to baseline. Although there was
an increase on EPI vaccine coverage in Mali 29% in
2001 to 48% in 2006 [24], the increase from 36.7% to
53.8% in the non intervention zone in one year is likely
due to IPTi implementation in other parts of the dis-
trict. The proportion of children completely vaccinated
after the IPTi implementation in the intervention zone
(69.5%) was consistent with a previous report in the dis-
trict of Kita in Mali, after three years of intense EPI vac-
cination priority program [37].
Our study also showed that high coverage (89% or
above) of IPTi can be obtained when the strategy is
implemented in the health system.
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To the best of our knowledge, this is the first study to
assess the impact of IPTi-SP on EPI vaccine coverage
using a cluster-randomized design. Additional studies
undertaken as part of the UNICEF pilot implementation
of IPTi-SP using pre-and post-implementation surveys,
although with more potential for bias, will provide
further insight on the impact of the strategy on the EPI
vaccines coverage. Like any study of its kind, the possi-
bility of founding these results by chance alone and or
as results of selection bias cannot be excluded. In our
study the coverage of vaccines and health intervention
tended to be higher in the intervention zone at baseline
although the differences were not statistically significant
(see additional file 2). Nevertheless the increase in vac-
cines coverage in both zones compared to baseline and
the fact that significantly higher coverage of vaccines
given with IPTi was found in intervention zone com-
pared to non -intervention are reassuring and indicate
that the IPTi implementation has played a role. If the
increase in EPI vaccines coverage is confirmed in other
studies, along with the recommendations of IPTi as pol-
icy by the WHO [38], decision-makers in sub-Saharan
Africa should consider rapid adoption and implementa-
tion of the strategy.
The use of ITN remained similar between the two
zones and compared to baseline, suggesting that the
IPTi implementation did not lower people’s attitudes on
malaria prevention.
Limitations of this study include i) the lack of control
intervention and blinding, ii) the fact that the training
was provided to staff of the all the health areas in the
district including in control zone and iii) the fact that
the strategy was implemented for only one year. In addi-
tion, because of the natural of the deployment, one can-
not control for “implementation slips” generated by the
lack of borders of community sensitization and the
migration between the two zones, although the propor-
tion of children who received IPTi in the control zone
was low (< 3%). Like with any new intervention of its
kind, continuous monitoring of its impact on the EPI
vaccine coverage will be needed along with the imple-
mentation of the strategy over longer period of time.
Conclusions
In summary, this study shows that high coverage of IPTi
can be obtained using routine health services and IPTi-
SP implementation resulted in a significant increase in
coverage of EPI vaccines in the district of Kolokani,
Mali, suggesting that the cost-effectiveness of the inter-
vention may be higher than reported and that low cov-
erage of the EPI vaccine should not preclude the
implementation of IPTi-SP.
Additional material
Additional file 1: Map of the health areas of the district of Kolokani,
Mali. The figure is a map of district of Kolokani, showing the health areas
(sub districts) with the intervention areas are indicated in red.
Additional file 2: Coverage of EPI vaccines by zone at baseline. The
table summarizes the coverage of EPI vaccines and other health
interventions based on the information on vaccination card and from
interview at baseline in intervention and control zones.
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